Extended Hormone Therapy Doesn't Help Some Prostate Cancer Patients: Study
Shorter-course treatment as effective for those with intermediate-risk disease, oncologist says
ConclusionsNon-tissue diagnosis of prostate cancer, while rare, is not outside normal clinical practice and is strongly associated with advanced patient age, higher clinical stage, multiple comorbidities, and very high PSA levels.
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
ngione Mario Pulvirenti Antonino Romeo Ugo De Giorgi The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years, and there is now an even greater need to understand the biological mechanisms of resistance and to develop noninvasive biomarkers to guide treatment. The androgen receptor (AR) is known to be involved in the pathogenesis and progression of prostate cancer. Recently, highly sensitive next-generation sequencing and PCR-based methods for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma were established in cell-free DNA (cfDNA) of patients with c...
Condition: Metastatic Castration-resistent Prostate Cancer Interventions: Drug: Docetaxel; Drug: Abiraterone Acetate or Enzalutamide Sponsor: National Cancer Institute, Naples Recruiting
CONCLUSIONS.—: Our understanding of neuroendocrine tumors of the prostate classification and diagnosis continues to evolve. These advances benefit the risk stratification and management of prostate cancer. PMID: 31644322 [PubMed - as supplied by publisher]
Conditions: Positive Lymph Node; Prostate Adenocarcinoma; PSA Level Greater Than Zero; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage I...